Connect Biopharma Holdings Limited Ordinary Shares

Day range

$0.75 – $0.89

Open

$0.79

Prev close

$0.77

Volume

1.75M

Market cap

$48.27M

Shares out

62.97M

P/E

—

P/S

16.42

P/B

1.81

P/FCF

—

ROE

-257.9%

ROA

-159.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsSep 30, 2026

  On September 30, 2026, the Company announced topline results for the COPD Study. The COPD Study is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of rademikibart as an adjunct to standard of care for acute exacerbations in participants with COPD and type 2 inflammation.

• Investor presentationSep 15, 2026

  A copy of presentation materials related to the Asthma Study, all or a part of which may be used by the Company in investor or scientific presentations from time to time, is furnished herewith as Exhibit 99.2.

• Private placementMar 30, 2026

  On March 29, 2026, Connect Biopharma Holdings Limited (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with the purchasers named therein (the "Purchasers"), for the private placement (the "Private Placement") of 6,130,000 shares (the "Shares") of the Company's ordinary shares, par value $0.000174 per share (the "Ordinary Shares"), at a price of $3.25 per Share... The aggregate gross proceeds for the Private Placement are expected to be approximately $20.2 million, before deducting offering fees and expenses.

• Director departureDec 23, 2025

  On December 17, 2025, Kan Chen, Ph.D., a partner at Qiming Venture Partners, notified Connect Biopharma Holdings Limited (the "Company") of his decision to resign from the Board of Directors of the Company (the "Board") and as a member of the Nominating and Corporate Governance Committee of the Board, effective immediately. Dr. Chen's resignation is not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Director appointmentJul 22, 2025

  On July 22, 2025, the Board of Directors (the "Board") of Connect Biopharma Holdings Limited (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee (the "Nominating Committee"), increased the size of the Board from six (6) to seven (7) directors and appointed James A. Schoeneck to fill the vacancy so created, effective immediately.

Days to cover

1.0

Short interest

3.5M

Avg volume

15.99M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
  positiveZacks Investment Research· Oct 19, 2026
• Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
  positiveGlobeNewswire Inc.· May 12, 2026
• Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
  positiveGlobeNewswire Inc.· Sep 4, 2025
• Connect Biopharma Posts Q2 Revenue Drop
  negativeThe Motley Fool· Aug 13, 2025
• Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
  neutralGlobeNewswire Inc.· Jul 18, 2025